Digestive organs: Liver: Combined hepatocellular and cholangiocarcinoma

Munechika Enjoji, Shinichi Aishima

Department of Hepatology and Pancreatology, Kyushu University Hospital, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan (ME); Department of Pathology, Hamanomachi Hospital, 3-5-27 Maizuru, Chuo-ku, Fukuoka 810-8539, Japan (SA)

Published in Atlas Database: September 2007
Online updated version: http://AtlasGeneticsOncology.org/Tumors/HepatoCholangioCarcinID5331.html
DOI: 10.4267/2042/38588
This work is licensed under a Creative Commons Attribution-Non-commercial-No Derivative Works 2.0 France Licence.
© 2008 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Identity

Other names: Hepatocellohiangiocellular carcinoma
Note: Defined as an intrahepatic tumor nodule that contains both hepatocellular carcinoma and cholangiocarcinoma.

Classification

Note: Tumor staging is separated by TNM classification. TNM classifications for hepatocellular and cholangiocarcinomas of the liver.

Clinics and pathology

Disease

Combined hepatocellular and cholangiocarcinoma is a more aggressive malignancy with a poorer prognosis than ordinary hepatocellular carcinoma (HCC).

Etiology

The reported frequency of combined hepatocellular and cholangiocarcinoma (combined tumors) varies widely; 1.0-6.5% among patients with primary liver cancer. Statistical data indicate that combined tumors occur predominantly in men (reported ratio is ranged from 14:1 to 2:1). The mean age of onset is in the sixth decade. In Asian cases, a high incidence of hepatitis B or C virus infection and frequent association of chronic liver disease/cirrhosis have been reported. Conversely, in Western countries, these features are less common. Combined tumors exhibit an invasive character with frequent venous permeation and tumor microsatellite formation, features that are seen more frequently than in ordinary HCC.

Epidemiology

A rare subtype of primary liver cancer.

Clinics

The typical clinical symptom is abdominal pain. Complaints of fatigue and weakness are mostly attributable to compromised liver function. Jaundice is found in a much lower percentage of patients than of those with intrahepatic cholangiocarcinoma (CC). Chills and fever appear rarely. In combined tumors, HCC and CC areas rarely can be identified using imaging techniques such as ultrasonography, helical CT, and dynamic MRI. In many cases, even in tumor biopsy samples, the two components are not included or discriminated. Generally, final diagnosis is entrusted to pathological findings of surgically resected or autopsy samples.

Pathology

The histopathological classification reported by Goodman et al. is popular:
- type I, in which HCC and CC occur coincidentally and no transitional forms are observed;
- type II, in which there are areas of apparent transition between HCC and CC;
- type III, in which tumor cells resemble the fibrolamellar subtype of HCC but contain mucin-producing glands.
Other classifications, reported by Allen and Lisa, and by Kojiro et al., are known.
Digestive organs: Liver: Combined hepatocellular and cholangiocarcinoma

Enjoji M, Aishima S


410

(A and B) Gross feature and schematic illustration of combined hepatocellular and cholangiocarcinoma. HCC: hepatocellular carcinoma, CC: cholangiocarcinoma. (C-E) Border zone between HCC and CC. Moderately differentiated HCC (right) with vague granular component (left). The granular tumor cells were positive for CK19 and HCC component was positive for Hep par-1.

Treatment
Surgical resection, chemotherapy, radiofrequency ablation, microwave coagulation, ethanol injection, transarterial embolization.

Evolution
Intrahepatic recurrence is common. Combined tumors have been reported to be more aggressive than HCC, with widespread metastasis and regional lymph node involvement.

Prognosis
The prognosis of combined tumors is poorer than that of HCC because of relatively frequent lymph node metastasis and vascular invasion. Survival rates of patients with combined tumors are generally poorer than those of patients with HCC.

Cytogenetics
Note: Loss of heterozygosity (LOH) at 4q, 8p, 13q, 16q, and 17p is seen frequently in combined hepatocellular and cholangiocarcinoma similar to in HCC. LOH at 3p and 14q are reported to be specific in CC and combined hepatocellular-cholangiocarcinoma in contrast to HCC.

Genes involved and Proteins

Genes
K-RAS

Location: 12p12.1
DNA/RNA
4 exons.

Protein
Proto-oncogene. GTP-GDP binding protein with GTPase activity. The K-ras proto-oncogene is thought to exert control over some of the mechanisms of cell growth and differentiation. This gene is converted to an active oncogene by point mutations concentrated significantly in codons 12, 13, and 61. Mutations of the K-ras gene have been reported to be common (67-75%) in intrahepatic CC. Conversely, the mutations rarely have been found in HCC. K-ras mutations in combined hepatocellular and cholangiocarcinoma have been analyzed in Japanese cases and it has been reported that the mutations were found rarely, as in the case for HCC. This observation may reflect the background of Japanese patients; specifically, chronic hepatitis C infection and evidence
of cirrhosis are found in a relatively high percentage of patients with combined hepatocellular and cholangiocarcinoma.

**p53**

*Location:* 17p13

*DNA/RNA*

11 exons.

*Protein*

Tumor suppressor. Wild-type p53 plays an important role in the regulation of the cell cycle process, cell growth, and apoptosis in the event of DNA damage. The aberrant proteins from the mutated genes disrupt critical growth-regulating mechanisms and may play a crucial role in the carcinogenesis. The reported incidence of p53 mutation is 11-37% in intrahepatic CC and 10-29% in combined hepatocellular and cholangiocarcinoma. In HCC, the frequency of p53 mutations varies among different geographic areas. p53 abnormalities appear not to be correlated with tumoral differentiation.

**References**


This article should be referenced as such: